<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14888">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245856</url>
  </required_header>
  <id_info>
    <org_study_id>10206</org_study_id>
    <secondary_id>ORA-20020622</secondary_id>
    <nct_id>NCT00245856</nct_id>
  </id_info>
  <brief_title>Treatment of Upper Extremity Deep-Vein Thrombosis</brief_title>
  <official_title>Treatment of Upper Extremity Deep-Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to document the long-term outcome or prognosis of patients
      diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin
      sodium injection) for three months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upper extremity deep-vein thrombosis (DVT) is an increasingly common clinical problem and
      has been found to cause important pulmonary embolism in up to 36% of cases including fatal
      embolism. The major risk factor for development of DVT is presence of a central venous
      catheter in which up to 30% of patients may develop venous thrombosis. Peripherally inserted
      central catheters or (PICC) lines have been more frequently used in order to avoid the
      morbidity of central venous catheter insertion. There is little data on the incidence of DVT
      with these catheters, or effective treatment regimen.

      The purpose of this study is to document the long-term outcome or prognosis of patients
      diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin
      sodium injection) for three months. About 100 patients will be enrolled in this study at the
      University of Oklahoma.

      All patients with upper extremity DVT will be screened. Each will have a complete baseline
      and risk factor assessment.

      All patients will receive active study drug for a period of 3 months with reassessment of
      upper extremity DVT by ultrasound.

      All patients will participate for a period of 12 months with follow up visits at 5-7 day,
      and 1, 3, 6, 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants That Died at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>New Venous Thromboembolism at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>New DVT or PE at 3 months confirmed by diagnostic testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Total major bleeding rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Deep-Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Treatment of Upper Extremity DVT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received dalterparin followed by warfarin or received dalterparin monotherapy for the treatment of upper extremity DVT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin sodium injection</intervention_name>
    <description>200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.</description>
    <arm_group_label>Treatment of Upper Extremity DVT</arm_group_label>
    <other_name>Fragmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Titrated to INR 2-3 through study month 3</description>
    <arm_group_label>Treatment of Upper Extremity DVT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed upper extremity DVT diagnosed by ultrasound imaging or
             venogram

        Exclusion Criteria:

          -  Active, clinically significant bleeding

          -  Known hypersensitivity to heparin or low-molecular weight heparin

          -  Currently pregnant or less than 1 week post-partum

          -  Acquired bleeding diathesis

          -  Known inherited bleeding disorder

          -  Renal failure

          -  Extremes of weight

          -  Poor performance status

          -  Unable to return for repeat diagnostic testing or follow-up visits
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman W. Rathbun, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma Health Science Center, Dept of Medicine/CardioVascular section</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Veterans Affairs Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Science Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 15, 2013</lastchanged_date>
  <firstreceived_date>October 26, 2005</firstreceived_date>
  <firstreceived_results_date>February 1, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oklahoma</investigator_affiliation>
    <investigator_full_name>Suman Rathbun</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Upper Extremity Deep-Vein Thrombosis</keyword>
  <keyword>DVT</keyword>
  <keyword>Fragmin</keyword>
  <keyword>Deep-Vein Thrombosis</keyword>
  <keyword>Thrombosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Upper Extremity Deep Vein Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period November 2002 to December 2008 OUHSC hospital and clinics: OU Medical Center and VA Medical Center</recruitment_details>
      <pre_assignment_details>Consecutive patients, both inpatient and outpatient, who had objectively confirmed upper extremity DVT found on standardized comprehensive duplex imaging or venogram. Ineligibility : predefined ineligibility criteria including high risk of bleeding.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dalteparin + Warfarin</title>
          <description>200 units per kg with transition Warfarin titrated to INR 2-3
This arm was completed and new treatment regimen was substituted for the remainder of the study.</description>
        </group>
        <group group_id="P2">
          <title>Dalteparin Only</title>
          <description>200 units/kg for one month At month one, dosage reduction based on weight</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period One</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period Two</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All DVT Treated Patients</title>
          <description>Participants received dalteparin 200units/kg followed by warfarin or dalteparin only for 3 months</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="56"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52" spread="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Died at 3 Months</title>
        <time_frame>3 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All DVT treated patients analyzed together</population>
        <group_list>
          <group group_id="O1">
            <title>All DVT Treated Patients</title>
            <description>Participants received dalteparin 200units/kg followed by warfarin or dalteparin only for 3 months</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants That Died at 3 Months</title>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>All cause mortality</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8" lower_limit="3" upper_limit="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Deaths attributed to DVT/PE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0">This confidence interval was not calculated</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>New Venous Thromboembolism at 3 Months</title>
        <description>New DVT or PE at 3 months confirmed by diagnostic testing</description>
        <time_frame>3 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All DVT treated patients analyzed together</population>
        <group_list>
          <group group_id="O1">
            <title>Dalteparin + Warfarin or Dalteparin Alone</title>
            <description>Patients with arm DVT who received either 3 months of dalteparin + warfarin (INR 2-3) or Dalteparin alone</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>New Venous Thromboembolism at 3 Months</title>
            <description>New DVT or PE at 3 months confirmed by diagnostic testing</description>
            <units>participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Events</title>
        <description>Total major bleeding rate</description>
        <time_frame>3 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All DVT treated patients analyzed together</population>
        <group_list>
          <group group_id="O1">
            <title>Dalteparin + Warfarin/Dalteparin Alone</title>
            <description>Major bleeding rates</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Bleeding Events</title>
            <description>Total major bleeding rate</description>
            <units>participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0" upper_limit="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dalteparin + Warfarin</title>
          <description>200 units per kg with transition Warfarin titrated to INR 2-3
This arm was completed and new treatment regimen was substituted for the remainder of the study.</description>
        </group>
        <group group_id="E2">
          <title>Dalteparin Only</title>
          <description>200 units/kg for one month At month one, dosage reduction based on weight</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suman Rathbun MD</name_or_title>
      <organization>University of Oklahoma Health Sciences Center</organization>
      <phone>4052714742 ext 44773</phone>
      <email>suman-rathbun@ouhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
